RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, announced that RT-IDea International BV will be the exclusive distributor of RTsafe’s products in Belgium, Luxemburg, Sweden and Norway.
RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create pseudo‐in‐vivo dosimetry phantoms towards End‐to‐End commissioning, benchmarking and patient‐specific quality assurance in SRS, IMRT, VMAT and SBRT applications. The anatomically accurate effigies enable medical professionals to plan more precise treatment interventions for each individual patient and help radiotherapy technology innovators to fine‐tune their products. The result is more effective individualized therapy and reduced patient risk. For more information, visit www.rt-safe.com.
Personalize your stereotactic quality assurance solutions with a PseudoPatient™ and improve your end to end QA.
RTsafe is providing innovative, 3D printed pseudo in-vivo phantoms and remote dosimetry services. Their solutions will provide cancer centers an elegant quality assurance (QA) solution by elevating confidence in the end-to-end accuracy of stereotactic systems and create wider access to advanced stereotactic treatments.
RTsafe’s PseudoPatient™ technology represents a new generation of dosimetry phantoms. Using a patient’s CT-scan and leveraging 3D printing utilizing bone and soft tissue mimicking materials, RTsafe provides anatomically accurate head phantoms that replicate the shape and dimensions of the patient’s head. The PseudoPatient phantoms are used by radiotherapy professionals to perform quality assurance and end-to-end testing of their SRS and SRT systems with a high-level of precision and accuracy. The phantoms provide confidence for SRS/SRT clinical use, high-resolution 3D dose verification and can also be used for routine End-to-End QA of complex radiotherapy treatments.
Read more on: Most advanced QA for Single Isocenter Multi-Focal SRS for Multiple Brain Metastases: End-to-End QA Results Related to 208 Targets
Groundbraking publication on randomized trial on ultra-hypofractionated radiotherapy, the HYPO-RT-PC phase 3! Fiducial markers will become even more important when applying ultra-hypofractionated radiotherapy for prostate cancer.
Congratulations to all the 12 Swedish and Danish centers that have contributed to the HYPO-RT-PC phase 3 trial!
|As the first published randomized trial on ultra-hypofractionated radiotherapy for prostate cancer, Lancet 18 2019, this groundbreaking study with 1,200 patients will lead to an increased use of ultra-hypofractionation. Fiducial markers play a key role in this development. To find out why, see GoldAnchorMarker.com.